Literature DB >> 9714055

Concomitant over-expression of activin/inhibin beta subunits and their receptors in human pancreatic cancer.

J Kleeff1, T Ishiwata, H Friess, M W Büchler, M Korc.   

Abstract

Activins and inhibins belong to the transforming growth factor-beta (TGF-beta) superfamily of multifunctional cytokines that bind to transmembrane receptors with serine/threonine kinase activity. In this study, we characterized the levels of expression of 3 activin/inhibin subunits (betaA, betaB, alpha), and 2 type I and type II activin receptors (actRI/Ib, actRII/IIb) in pancreatic cancer cell lines and in human pancreatic tissues. In addition, we assessed the growth responsiveness to activin A in these cell lines. All 6 cell lines (ASPC-1, CAPAN-1, COLO-357, MIA-PaCa-2, PANC-1 and T3M4) expressed the activin/inhibin betaA subunit, whereas expression levels of the activin/inhibin betaB and alpha subunits were undetectable. Furthermore, actRI, actRII and actRIIb were expressed in all cell lines and actRIb mRNA was evident in ASPC-1, CAPAN-1, COLO-357 and PANC-1 cells. CAPAN-I and COLO-357 cells were growth-stimulated by activin A in the presence of 10% serum, whereas the other cell lines were resistant to activin A. In contrast, in serum-free medium activin A inhibited the growth of CAPAN-1, COLO-357 and MIA-PaCa-2 cells. Pancreatic cancer samples markedly over-expressed the activin/inhibin betaA subunit, whereas the betaB subunit was only moderately increased in comparison to normal pancreatic samples. Pancreatic cancer tissues also markedly over-expressed actRI, actRIb and actRII. By in situ hybridization, activin/inhibin betaA, actRI, actRIb and actRII were strongly expressed in diffuse infiltrative and duct-like cancer cells. Both the ligand and its receptors were often co-expressed in these cells. Together, our findings suggest that activin A may participate in autocrine activation of pancreatic cancer cells in vivo.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9714055     DOI: 10.1002/(sici)1097-0215(19980911)77:6<860::aid-ijc11>3.0.co;2-5

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  16 in total

1.  Activin type 2 receptor restoration in MSI-H colon cancer suppresses growth and enhances migration with activin.

Authors:  Barbara H Jung; Stayce E Beck; Jennifer Cabral; Eddy Chau; Betty L Cabrera; Antonio Fiorino; E Julieta Smith; Melanie Bocanegra; John M Carethers
Journal:  Gastroenterology       Date:  2006-11-16       Impact factor: 22.682

2.  Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma.

Authors:  Christopher W Seder; Wibisono Hartojo; Lin Lin; Amy L Silvers; Zhuwen Wang; Dafydd G Thomas; Thomas J Giordano; Guoan Chen; Andrew C Chang; Mark B Orringer; David G Beer
Journal:  Neoplasia       Date:  2009-04       Impact factor: 5.715

3.  Differentiation of single cell derived human mesenchymal stem cells into cells with a neuronal phenotype: RNA and microRNA expression profile.

Authors:  Francesca Crobu; Veronica Latini; Maria Franca Marongiu; Valeria Sogos; Franca Scintu; Susanna Porcu; Carla Casu; Manuela Badiali; Adele Sanna; Maria Francesca Manchinu; Maria Serafina Ristaldi
Journal:  Mol Biol Rep       Date:  2011-07-20       Impact factor: 2.316

4.  Overexpression of Smad2 and colocalization with TGF-beta1 in human pancreatic cancer.

Authors:  J Kleeff; H Friess; P Simon; S Susmallian; P Büchler; A Zimmermann; M W Büchler; M Korc
Journal:  Dig Dis Sci       Date:  1999-09       Impact factor: 3.199

5.  Clinical Significance of INHBA Gene Expression in Patients with Gastric Cancer who Receive Curative Resection Followed by Adjuvant S-1 Chemotherapy.

Authors:  Yusuke Katayama; Takashi Oshima; Kentaro Sakamaki; Toru Aoyama; Tsutomu Sato; Katsuhiko Masudo; Manabu Shiozawa; Takaki Yoshikawa; Yasushi Rino; Toshio Imada; Munetaka Masuda
Journal:  In Vivo       Date:  2017 Jul-Aug       Impact factor: 2.155

6.  Overexpression of activin A in stage IV colorectal cancer.

Authors:  S Wildi; J Kleeff; H Maruyama; C A Maurer; M W Büchler; M Korc
Journal:  Gut       Date:  2001-09       Impact factor: 23.059

7.  Activin A circulating levels in patients with bone metastasis from breast or prostate cancer.

Authors:  Gaetano Leto; Lorena Incorvaia; Giuseppe Badalamenti; Francesca M Tumminello; Nicola Gebbia; Carla Flandina; Marilena Crescimanno; Giovambattista Rini
Journal:  Clin Exp Metastasis       Date:  2006-07-14       Impact factor: 5.150

8.  Low expression of INHB co-receptor TGFBR3 in connection with metastasis and immune infiltration in lung adenocarcinoma.

Authors:  Guoying Zou; Ying Wu; Biqiong Ren; Yuanyuan Wu; Qing Zhu; Junyu He; Zhihong Luo
Journal:  Am J Transl Res       Date:  2022-08-15       Impact factor: 3.940

Review 9.  Pathways for aberrant angiogenesis in pancreatic cancer.

Authors:  M Korc
Journal:  Mol Cancer       Date:  2003-01-07       Impact factor: 27.401

10.  Cancer Stem Cells, EMT, and Developmental Pathway Activation in Pancreatic Tumors.

Authors:  Sanne Hindriksen; Maarten F Bijlsma
Journal:  Cancers (Basel)       Date:  2012-10-12       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.